Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent

Daniel P. Ball; Andrew M. Lewis; Declan Williams; Diana Resetca; Derek J. Wilson; Patrick T. Gunning

doi:10.18632/oncotarget.7838

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent

Daniel P. Ball, Andrew M. Lewis, Declan Williams, Diana Resetca, Derek J. Wilson and Patrick T. Gunning _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:20669-20679. https://doi.org/10.18632/oncotarget.7838

Metrics: PDF 2525 views | HTML 2684 views | ?

Abstract

Daniel P. Ball1,*, Andrew M. Lewis1,*, Declan Williams2,3, Diana Resetca4, Derek J. Wilson2,3, Patrick T. Gunning4

1Department of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga, Ontario, L5L 1C6, Canada

2Department of Chemistry, York University, Toronto, Ontario, M3J 1P3, Canada

3Department of Chemistry, Center for Research in Mass Spectrometry, York University, Toronto, Ontario, M3J 1P3, Canada

4Department of Medical Biophysics, University of Toronto, Toronto, Ontario, M5G 1L, Canada

*These authors have contributed equally to this work

Correspondence to:

Patrick T. Gunning, e-mail: [email protected]

Keywords: STAT3, S3I-201, NSC 74859, covalent modification, oncology

Received: October 15, 2015 Accepted: January 29, 2016 Published: March 02, 2016

ABSTRACT

The Signal Transducer and Activator of Transcription 3 (STAT3) oncogene is a master regulator of many human cancers, and a well-recognized target for therapeutic intervention. A well known STAT3 inhibitor, S3I-201 (NSC 74859), is hypothesized to block STAT3 function in cancer cells by binding the STAT3 SH2 domain and disrupt STAT3 protein complexation events. In this study, liquid chromatography tandem mass spectrometry analysis revealed that STAT3, in the presence of S3I-201, showed a minimum of five specific sites of modification, cysteine’s 108, 259, 367, 542, and 687. Moreover, a prepared fluorescently labeled chemical probe of S3I-201 (DB-6-055) revealed that S3I-201 non-specifically and globally alkylated intracellular proteins at concentrations consistent with S3I-201’s reported IC₅₀. These data are consistent with the hypothesis that S3I-201 is a sub-optimal probe for interrogating STAT3-related cell biology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7838

Publication Alerts

Research Papers:

Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent

Abstract